Back to discover
Disease

Adenomatous Polyposis Coli

Late-stage therapeutic developmentEmerging researchRising momentum
MeSHAdenomatous Polyposis Coli
3
Publications
10
Clinical trials
2025
Latest publication
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this disease.

What's happening now

An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.

Executive briefingUpdating summary…Momentum: Low
Key developments
  • 1 clinical trial expected to report results, the earliest in Q1 2029.
Upcoming Milestones
Clinical Milestones1View
Results expected 1
Activity timeline1

Clinical trials

8 sponsors · 1 new · 0 completed in the last 12 months (net +1)

The current development programme across all trial phases.

Clinical programme
10
All trials
1
Active
3
Late-stage
6
Completed
Recently completed

A Phase 1b Study to Evaluate the Efficacy and Safety of JNJ-64251330, a Janus Kinase (JAK) Inhibitor, in Participants With Familial Adenomatous Polyposis

Phase 1 · Completed · Janssen Research & Development, LLC

A Phase 1b, Multicenter, Randomized, Blinded, Placebo-controlled Study to Evaluate the Efficacy of Guselkumab in Subjects With Familial Adenomatous Polyposis

Phase 1 · Completed · Janssen Research & Development, LLC

Sirolimus for the Treatment of Severe Intestinal Polyposis in Patients With Familial Adenomatous Polyposis (FAP): a Pilot Study

Phase 2 · Completed · Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

Visualization of a VEGF-targeted Near-Infrared Fluorescent Tracer in Patients With Familial Adenomatous Polyposis During Fluorescence Endoscopy A Single Center Pilot Intervention Study

Phase 1 · Completed · University Medical Center Groningen

Genetic Events Leading to APC-Dependent Colon Cancer in High-Risk Families; a Clinical Trial of COX and EGFR Inhibition in Familial Polyposis Patients

Phase 2 · Completed · University of Utah

A Two-Arm Chemoprevention Trial in Familial Adenomatous Polyposis (FAP) Coli Patients Using the Purified Free Fatty Acid, Eicosapentaenoic Acid

Phase 2/3 · Completed · S.L.A. Pharma AG

Research activity

3 papers

Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.

Publications over time
20032025
Major themes3
  • Adenomatous Polyposis Coli1
  • Capsule Endoscopy1
  • Double-Balloon Enteroscopy1
Leading journals3
  • Endoscopy1
  • Familial cancer1
  • The New England journal of medicine1
Leading researchers8
  • Adler SN1
  • Albert J1
  • Baltes P1
  • Barbaro F1
  • Buchanan DD1
  • Cellier C1
  • Charton JP1
  • de la Chapelle A1
Affiliations (unnormalised)6
  • Catalan Institute of Oncology1
  • Catholic University1
  • Centre Hospitalier Lyon Sud1
  • Centro Hospitalar do Alto Ave1
  • Chaim Sheba Medical Center1
  • Clinical Psychology Unit1

Reference

Authoritative identity, definition & identifiers.

Defined in MeSH

A polyposis syndrome due to an autosomal dominant mutation of the APC genes (GENES, APC) on CHROMOSOME 5. The syndrome is characterized by the development of hundreds of ADENOMATOUS POLYPS in the COLON and RECTUM of affected individuals by early adulthood.

Identifiers
MeSHAdenomatous Polyposis Coli
References & data sources
  • Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
  • Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
  • Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
  • Related entities are derived from literature co-mention (studied together) — associative, not causal.